
| Written | 1999-10 | Claude Viguié |
| Service de Dermatologie, Hôpital Tarnier-Cochin, 89 rue d'Assas, 75006 Paris, France |
| Identity |
| Other names | Familial atypical mole-malignant melanoma syndrome (FAMMM) |
| B-K mole syndrome | |
| Atlas_Id | 10013 |
| Genes implicated in | CDKN2A CDKN2C TP53BP1 |
| Inheritance |
autosomal dominant with high penetrance and variable expressivity; the frequency of DNS is difficult to evaluate because a number of cases without malignant evolution are not recorded; DNS defines patients with numerous dysplastic nevi. FAMMM defines families where coexist numerous nevi with malignant melanoma (MM) sporadic forms of dysplastic nevi are not considered as DNS |
| Clinics |
| Note | the familial dysplastic nevus syndrome is a good example of a genetic disorder which leads to the practice of self prevention and prevention at the family level; the risk is the evolution towards MM |
| Phenotype and clinics | predominant in patients with a clear complexion, blue eyes and/or presence of numerous nevi; the dysplastic nevus or "nevus of Clark" or "atypical melanocytic nevus" is a large mole with a variable size (5 to 15 mm), an irregular border and a color varying from dark brown to depigmentation; lesions are located mainly on the upper trunk, back, limbs, abdomen and arms; the number of moles is variable, from 10 to up to 100 |
![]() | |
| Neoplastic risk | the main risk is to develop a MM but there is also a possible increased incidence of pancreatic cancer, breast cancer, and myeloma; MM usually arises from a dysplastic nevus (DN) but it can also appear de novo or from a benign nevus; it occurs most often in the skin but it may also involve other sites, mainly the eye or the central nervous system; the risk of MM depends on three factors: |
| Treatment | clinical vigilance and tumour exeresis |
| Evolution | the number of DN can increase during life with an increase in MM risk |
| Prognosis | according to the tumour expansion at the time of exeresis |
| Cytogenetics |
| Inborn conditions | a chromosome instability disorder was observed in cell cultures from the normal skin and dysplastic nevi over three-generations in DNS families, leading to translocations, duplications and deletions; in another study on MM, translocations involving bands 11q24, 1q25 and Xq13 were observed in patients with DNS, in dysplastic nevi and in the normal skin as well; a loss of chromosome 9 was found in 2 out of 4 DN, suggesting that deletion / inactivation of a gene on 9p may be a primary event in melanocyte transformation; loss of heterozygocity (LOH) for markers flanking the CDKN2A on 9p was described in primary MM and in a metastasis; other putative tumor suppressor genes which could be involved in the process are located in 1p13, 10p, 10q, 11q and 6q15-q23 DNS is characterized cytogeneticaly by an UV-induced elevated level of sister chromatid exchange (SCE); the post-UV plasmid hypermutability test is a laboratory marker for FAMMM patients, suggesting a defective repair mechanism of UV-induced DNA damage; deficient DNA repair in lymphocyte studies also characterizes some patients with sporadic dysplastic nevi or non familial MM |
| Genes involved and Proteins |
| Gene Name | still unknown |
| Location | locus in 1p36 (called CMM1 for cutaneous malignant melanoma): this locus segregates with MM and DNS, but no gene is yet cloned |
| Gene Name | CDKN2C/p18 (cyclin-dependent kinase inhibitor 2) |
| Location | locus in 1p32; this locus has been found mutated in the germline from patients with MM and other tumors |
| Gene Name | CDKN2A/p16/MTS1/CDK4 inhibitor (cyclin-dependent kinase inhibitor 2A) |
| Location | locus in 9p21; this locus has been designated as CMM2; germline mutations were found in this locus in 30 to 40% of patients with FAMMM, and in some patients with two cutaneous and/or mucous MM; P16 is a candidate gene for MM susceptibility; there is a p16 mutation in 10 to 14% of patients suffering from sporadic multifocal MM; P16 is also involved in several other types of cancers; other tumor suppressor genes located at 9p are hypothetically involved in MM progression |
| Gene Name | CDK4 (cyclin dependent kinase) |
| Location | locus in 12q14; 2 germline mutations found in 3 FAMMM families |
| Gene Name | still unknown |
| Location | locus in 6q: a 6q allelic loss was identified in 21 of 53 informative loci; the chromosomal region bearing the highest frequency of 6q allelic loss was defined by the markers MYB and ESR located at 6q22-q23 and 6q24-q27, respectively; this may indicate genetic heterogeneity |
| Gene Name | MC1R (melanocortin receptor) |
| Location | locus in 16q24.3; defined as possible susceptibility gene |
| Gene Name | TP53 |
| Location | 17p13; P53 mutations were found in benign and dysplastic nevi from patients with previous personal or familial history of MM; however, these mutations are considered to be late events and cannot be used as a marker to identify patients at high risk of MM |
| Bibliography |
| Characteristics of familial and non-familial melanoma in Australia. |
| Ang CG, Kelly JW, Fritschi L, Dowling JP |
| Melanoma research. 1998 ; 8 (5) : 459-464. |
| PMID 9835460 |
| A review of inherited predisposition to melanoma. |
| Cannon-Albright LA, Kamb A, Skolnick M |
| Seminars in oncology. 1996 ; 23 (6) : 667-672. |
| PMID 8970585 |
| Dysplastic nevi as a melanoma risk factor in patients with familial melanoma. |
| Carey WP Jr, Thompson CJ, Synnestvedt M, Guerry D 4th, Halpern A, Schultz D, Elder DE |
| Cancer. 1994 ; 74 (12) : 3118-3125. |
| PMID 7982177 |
| Cytogenetic analysis in melanoma and nevi. |
| Cowan JM, Francke U |
| Cancer treatment and research. 1991 ; 54 : 3-16. |
| PMID 1673858 |
| Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p, and evidence for genetic heterogeneity. |
| Goldstein AM, Dracopoli NC, Engelstein M, Fraser MC, Clark WH Jr, Tucker MA |
| American journal of human genetics. 1994 ; 54 (3) : 489-496. |
| PMID 8116618 |
| Acquired precursors of cutaneous malignant melanoma. The familial dysplastic nevus syndrome. |
| Greene MH, Clark WH Jr, Tucker MA, Elder DE, Kraemer KH, Guerry D 4th, Witmer WK, Thompson J, Matozzo I, Fraser MC |
| The New England journal of medicine. 1985 ; 312 (2) : 91-97. |
| PMID 3964923 |
| Dysplastic nevus syndrome: intrafamilial identification of carriers by cytogenetics. |
| Hürlimann AF, Bohnert E, Schnyder UW, Jung EG |
| Dermatology (Basel, Switzerland). 1992 ; 184 (3) : 223-225. |
| PMID 1392119 |
| Germline mutations of the CDKN2 gene in UK melanoma families. |
| Harland M, Meloni R, Gruis N, Pinney E, Brookes S, Spurr NK, Frischauf AM, Bataille V, Peters G, Cuzick J, Selby P, Bishop DT, Bishop JN |
| Human molecular genetics. 1997 ; 6 (12) : 2061-2067. |
| PMID 9328469 |
| Chromosome rearrangements in dysplastic nevus syndrome predisposing to malignant melanoma. |
| Hecht F, Hecht BK |
| Cancer genetics and cytogenetics. 1988 ; 35 (1) : 73-78. |
| PMID 3180013 |
| Overexpression of p53 is a late event in the development of malignant melanoma. |
| Lassam NJ, From L, Kahn HJ |
| Cancer research. 1993 ; 53 (10 Suppl) : 2235-2238. |
| PMID 8485708 |
| Melanoma precursors in children. |
| Lefkowitz A, Schwartz RA, Janniger CK |
| Cutis; cutaneous medicine for the practitioner. 1999 ; 63 (6) : 321-324. |
| PMID 10388950 |
| Detection of p53 mutations in benign and dysplastic nevi. |
| Levin DB, Wilson K, Valadares de Amorim G, Webber J, Kenny P, Kusser W |
| Cancer research. 1995 ; 55 (19) : 4278-4282. |
| PMID 7671235 |
| Hypermutability of UV-treated plasmids in dysplastic nevus/familial melanoma cell lines. |
| Moriwaki SI, Tarone RE, Tucker MA, Goldstein AM, Kraemer KH |
| Cancer research. 1997 ; 57 (20) : 4637-4641. |
| PMID 9377580 |
| Melanocytic nevi, dysplastic nevi, and malignant melanoma in children from melanoma-prone families. |
| Novakovic B, Clark WH Jr, Fears TR, Fraser MC, Tucker MA |
| Journal of the American Academy of Dermatology. 1995 ; 33 (4) : 631-636. |
| PMID 7673498 |
| Cytogenetic study of neoplastic and nonneoplastic cells of the skin. |
| Pavarino EC, Antonio JR, Pozzeti EM, Larranãga HJ, Tajara EH |
| Cancer genetics and cytogenetics. 1995 ; 85 (1) : 16-19. |
| PMID 8536232 |
| Screening of germline mutations in the CDK4, CDKN2C and TP53 genes in familial melanoma: a clinic-based population study. |
| Platz A, Hansson J, Ringborg U |
| International journal of cancer. Journal international du cancer. 1998 ; 78 (1) : 13-15. |
| PMID 9724087 |
| Inherited susceptibility to several cancers but absence of linkage between dysplastic nevus syndrome and CDKN2A in a melanoma family with a mutation in the CDKN2A (P16INK4A) gene. |
| Puig S, Ruiz A, Castel T, Volpini V, Malvehy J, Cardellach F, Lynch M, Mascaro JM, Estivill X |
| Human genetics. 1997 ; 101 (3) : 359-364. |
| PMID 9439668 |
| Radiation-induced chromatid breaks and DNA repair in blood lymphocytes of patients with dysplastic nevi and/or cutaneous melanoma. |
| Sanford KK, Parshad R, Price FM, Tarone RE, Thompson J, Guerry D |
| The Journal of investigative dermatology. 1997 ; 109 (4) : 546-549. |
| PMID 9326388 |
| Dysplastic nevi in relation to superficial spreading melanoma. |
| Titus-Ernstoff L, Barnhill RL, Duray PH, Ernstoff MS, Kirkwood JM |
| Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 1993 ; 2 (2) : 99-101. |
| PMID 8467253 |
| Citation |
| This paper should be referenced as such : |
| Viguié, C |
| Dysplastic nevus syndrome (DNS) |
| Atlas Genet Cytogenet Oncol Haematol. 1999;3(4):212-214. |
| Free journal version : [ pdf ] [ DOI ] |
| On line version : http://AtlasGeneticsOncology.org/Tumors/DysplNevusID10013.html |
| External links |
| OMIM | 155600 |
| OMIM | 155601 |
| Orphanet | Familial atypical multiple mole melanoma syndrome |
| MeSH | D004416 |
| MedGen | D004416 |
| UMLS | - |
| HGMD | 335362 |
| REVIEW articles | automatic search in PubMed |
| Last year articles | automatic search in PubMed |
| © Atlas of Genetics and Cytogenetics in Oncology and Haematology | indexed on : Fri Jun 30 11:24:16 CEST 2017 |
For comments and suggestions or contributions, please contact us